Listed

Edwards Lifesciences Corp: Form 10-Q for the period ended Mar 31, 2020

Filed with the SEC on Apr 28, 2020 and accepted by EDGAR at Apr 27, 2020, 19:56 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-01-01 to 2020-03-31$1.13bnus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-01-01 to 2020-03-31$265.1mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-01-01 to 2020-03-31$863.6mus-gaap:GrossProfit
Research and development3 months2020-01-01 to 2020-03-31$187.4mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-01-01 to 2020-03-31$307.8mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-01-01 to 2020-03-31$358.1mus-gaap:OperatingIncomeLoss
Income tax3 months2020-01-01 to 2020-03-31$53.9mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2020-01-01 to 2020-03-31$310.6mus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Diluted EPS3 months2020-01-01 to 2020-03-31$1.47us-gaap:EarningsPerShareDiluted
Basic EPS3 months2020-01-01 to 2020-03-31$1.49us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2020-01-01 to 2020-03-31211,700,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2020-01-01 to 2020-03-31$207.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2020-01-01 to 2020-03-31$82.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases3 months2020-01-01 to 2020-03-31$614.8mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2020-03-31$662.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-03-31$2.51bnus-gaap:AssetsCurrent
Total assetsAt period end2020-03-31$6.08bnus-gaap:Assets
Current liabilitiesAt period end2020-03-31$746.9mus-gaap:LiabilitiesCurrent
Long-term debtAt period end2020-03-31$594.6mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-03-31$3.90bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001099800-20-000009. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.